unverified Tirzepatide injectable Compounded tirzepatide advertised from $199/mo, plus a Mochi membership of $39 the first month then $79/mo
Approval of drugs for use can lead to significant stock price increases, as too can collaborations with pharmaceutical companies or acquisitions
Over the past few years, this sector has shown dramatic growth: the Korea CRO industrys workforce grew by 47.4% in the last 3 years, and CRO revenue in Korea jumped 77.7% over the past 5 years
Evaluation: Body fat (DXA scanning) Lean mass Insulin sensitivity Energy expenditure What they found: The combination showed an additive effect on fat reduction vs monotherapy AOD-9604 partially protected lean mass during GLP-1-induced weight reduction Increased energy expenditure in combination (~3 % vs GLP-1 alone) No new safety signals Why it matters: It validates the concept of combination , the idea that AOD-9604 may not work on its own, but can add value in combination with incretin agonists
Since compounded products are not FDA-approved, advertisements for them, including on a companys website, should avoid claiming the products are safe or effective for treating any condition
Speaking on RT's Today with Claire Byrne, Professor Caitriona Ryan, Consultant Dermatologist with the Institute of Dermatologists and Blackrock Clinic, reiterated the concerns expressed by the HPRA